Alaunos Therapeutics Acquired Velaris and Raised $350M
The pharmaceutical company completed its acquisition of Velaris Therapeutics alongside a major private capital raise.
Updated on Oct. 13, 2026 in Healthcare
Live Poll
Do you trust the long-term viability of small biotechnology companies after major acquisitions?
Alaunos Therapeutics has finalized its acquisition of Velaris Therapeutics and secured $350 million in new private placement financing. This strategic move aims to expand the company's research pipeline into pulmonary arterial hypertension.
Why it matters
The capital injection is intended to stabilize the company's financial position and sustain operations through 2029. It specifically funds the development of new clinical trial assets, including the VLR199 program.
The company raised $350 million in new funding compared to a cash balance of just $120,000 as of June 30, 2026. This capital is projected to fund company operations and clinical research through 2029.
The players
Alaunos Therapeutics
This biotechnology company focuses on the development of novel cancer and pulmonary arterial hypertension therapies.
Velaris Therapeutics
This company specializes in the development of treatments for pulmonary arterial hypertension.
Nasdaq
This global stock exchange operator regulates listed companies and issues notices regarding compliance with listing standards.
Peter Harwin
He is an incoming member of the Alaunos board of directors.
The details
The transaction includes the addition of Velaris assets VLR199, VLR247, VLR258, and VLR360 to the Alaunos portfolio. The acquisition and financing were approved by the boards of both companies and Velaris stockholders.
Timeline
June 30, 2026: Alaunos reported cash and cash equivalents of $120,000.
October 9, 2026: Nasdaq issued a delisting notice to Alaunos.
October 13, 2026: The acquisition of Velaris Therapeutics was completed.
2028: Proof-of-concept data for VLR199 is expected.
2029: Operations are expected to be fully funded through this period.
Market Landscape
This move follows a recurring pattern where small-cap biotech firms use significant capital raises to stabilize operations following a Nasdaq Minimum Bid Price delisting notice. By pivoting their pipeline and securing new funding, these firms attempt to improve their standing among institutional investors and regain market compliance.
Investors and stakeholders should note that the company has secured a significant funding runway to support its clinical programs through 2029. The acquisition effectively integrates new drug assets into the corporate portfolio, altering the company's research focus and long-term product pipeline.
The takeaway
The acquisition and financing represent a critical pivot for Alaunos as it attempts to move past recent financial instability and delisting threats. Investors should monitor progress toward the 2028 proof-of-concept data for the VLR199 program to assess the success of this strategic transition.
Further reading
For more on industry developments, visit the United States Healthcare section.
Source note: This article includes information reported by TokenPost.
Live Poll
Do you trust the long-term viability of small biotechnology companies after major acquisitions?
